FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
Steady: 0 in the last 7 days
Updated oct 22
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.ProKidney is advancing its Phase 3 PROACT 1 study.1 source
- ProKidney Corp. received RMAT designation from the FDA and filed a Current Report on Form 8-K with the SEC.Sub-event
FDA granted eligibility for accelerated approval for ProKidney Corp.1 source
ProKidney's Rilparencel received RMAT designation from the FDA.1 source
Keep exploring
The entities involved
Related events
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- FDA approval supports NDA submission in Aurora.
- FDA granted accelerated approval for VOCERYQ, causing INOVIO stock to lead Nasdaq gainers.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Adam Craig reported positive results that could support FDA approval for a treatment.
Coverage
Newest first; wire copies grouped- manilatimes.net
- ZacksPROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase
- GlobeNewswireProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company
- Unknown outlet